New Vaccines Approved for Use in 2017

By Luis G. de Jesus, MD

Heplisav-B

Hepatitis B Vaccine recombinant

Indication: Prevention of Hepatitis B infection for adults 18 years of age or older

Dosing: 2 doses, 1 month apart

Advantages: (compared to older vaccines)

  • Two-dose hepatitis B vaccine for adults (instead of three doses)
  • Higher rate of protection (95% vs. 81%).
  • Promising vaccine for “non-responders” to older Hepatitis B vaccines (awaiting studies).

Shingrix

Zoster Vaccine recombinant

Indication: Prevention of herpes zoster (shingles) in adults aged 50 years and older

Dosing: 2 doses, 2-6 months apart

Advantages: (compared to older vaccine)

  • Higher efficacy (90%) across all age groups).
  • Provides longer and more persistent protection.
  • Not a “live-virus” vaccine thus a promising vaccine for patients with weakened immune (awaiting studies).